[Clinical feasibility of imaging with indocyanine green combined with methylene blue for sentinel lymph node identification in papillary thyroid microcarcinoma]

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Objective:To explore the value of indocyanine green（ICG） combined with methylene blue in the identification of sentinel lymph nodes（SLNs） in patients diagnosed with papillary thyroid microcarcinoma（PTMC）.

Why It Was Studied

ICG combined with methylene blue were injected into the thyroid in group A, and only methylene blue were injected into thyroid in group B.

Blue-stained or fluorescent nodes observed using near-infrared fluorescence imaging systems were defined as SLNs.

Who Took Part

The study group was 45 patients.

Methods:Ninety patients were enrolled and were randomized into group A and group B with 45 patients in each group.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

What Was Measured

The pathological data and postoperative outcomes were compared between two groups.

The subject headings attached to it are Carcinoma, Papillary, Coloring Agents, Feasibility Studies, Indocyanine Green, Lymph Nodes, Methylene Blue and Sentinel Lymph Node.

Author keywords: sentinel lymph nodes and thyroid neoplasms.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 45 patients.

The publication is from 2021 (Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery), a journal based in China.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.